IPHA News and Press, Innate Pharma S.A. From 03/27/25

FDA Breakthrough Therapy Designation granted to lacutamab for relapsed or refractory Sézary syndrome New data, including lacutamab improved health-related quality of life data from TELLOMAK Phase 2 study in patients with cutaneous T cell lymphoma were presented at ASH 2024 ...

IPH4502 is a novel and differentiated exatecan ADC targeting Nectin-4, currently investigated in a Phase 1 clinical trial in advanced solid tumors. IPH4502 demonstrated preclinical anti-tumor efficacy in models of primary and acquired resistance to enfortumab vedotin and in tumors wit...

Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“ Innate ” or the “ Company ”) today announced that members of its executive team are scheduled to participate in the upcoming investor conference, detailed below: Life Sciences Va...

2025-03-21 09:10:35 ET Summary Innate Pharma's diverse pipeline, including lacutamab, IPH6501, and IPH4502, shows promising clinical activity and potential for significant milestones in 2025. Lacutamab, a key asset, received US FDA Breakthrough Therapy designation, enhancing its d...

Papaya Growth Opportunity Corp. I (PPYA) is expected to report for quarter end 2024-12-31 KinderCare Learning Companies Inc. (KLC) is expected to report $0.04 for Q4 2024 Recordati SpA (RCDTF) is expected to report for quarter end 2024-12-31 InflaRx N.V. (IFRX) is expected to report $...

Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“ Innate ” or the “ Company ”), today announces that the Company will hold a conference call on Thursday, March 27, 2025 at 2 p.m. CET / 9 a.m. EDT, following the release of its financia...

Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“ Innate ” or the “ Company ”) today announced that members of its executive team will present and host 1x1 meetings at the Leerink Partners 2025 Global Healthcare Conference being held ...

2025-02-20 11:39:25 ET Summary Positive results achieved in the open-label phase 2 TELLOMAK study, using lacutamab for the treatment of patients with relapsed/refractory Sezary Syndrome; Patients achieved a confirmed Objective Response Rate of 37.5%. Release of data from phase 2 s...

2025-02-18 13:49:24 ET More on Innate Pharma, Merus, etc. Time To Upgrade Merus N.V. To A 'Buy' After The Recent Selloff Innate Pharma: Looking Like A Company We'll Regret Ignoring Merus and Biohaven to co-develop three novel bispecific ADC programs Innate Ph...

Designation is based on TELLOMAK Phase 2 results demonstrating efficacy and a favorable safety profile in patients with advanced Sézary syndrome heavily pre-treated, post- mogamulizumab. Breakthrough Therapy Designation is intended to accelerate the development and regulatory rev...